在1p13胆固醇位点通过SORT1从非编码变异转变为表型
Kiran Musunuru1, Alanna Strong, Maria Frank-Kamenetsky
1Cardiovascular Research Center and Center for Human Genetic Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
Nature
|August 6, 2010
概括
接近SORT1基因的常见遗传变异通过改变肝脏如何产生非常低密度脂蛋白颗粒来影响胆固醇水平和心脏病发作风险. 这一发现揭示了管理脂蛋白代谢和心血管疾病风险的新途径.
科学领域:
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
- 心血管疾病研究研究
背景情况:
- 全基因组关联研究 (GWAS) 确定了与低密度脂蛋白胆固醇 (LDL-C) 和心肌梗塞 (MI) 相关的1p13染色体上的位点.
- 连接这种基因位点与临床表型的确切功能机制尚不清楚.
研究的目的:
- 阐明1p13位元多态 (1p13位元多态) (rs12740374) 在脂蛋白代谢和心血管风险中的功能作用.
- 调查这种变异如何影响肝脏基因表达和非常低密度脂蛋白 (VLDL) 分泌.
主要方法:
- 对人类队列和肝细胞研究的分析.
- 研究rs12740374多态对CCAAT/增强剂结合蛋白 (C/EBP) 转录因子结合的影响.
- 在小鼠肝脏模型中利用小干扰RNA (siRNA) 敲除和SORT1基因的病毒过度表达.
主要成果:
- rs12740374的多态性产生了一个C/EBP结合部位,改变肝脏SORT1基因表达.
- 在小鼠中Sort1调节通过影响肝脏VLDL分泌直接影响血LDL-C和VLDL水平.
- 证明来自GWAS的常见非编码DNA变异可以直接影响临床结果.
结论:
- 确定了一种涉及SORT1基因的新型脂蛋白代谢调节途径.
- 功能性证据支持1p13位点在通过脂蛋白调节调节心脏病发作风险方面的作用.
- 确立了常见的非编码遗传变异可以对复杂的人类疾病产生直接影响.
相关概念视频
Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genetic Lingo
Overview


